Form 4: Regulus Therapeutics CFO Sells Shares to Cover Tax Obligations

Crispina Calsada, CFO of Regulus Therapeutics, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs) under a pre-existing 10b5-1 plan.

Summary

• Crispina Calsada, the Chief Financial Officer of Regulus Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On January 13, 2025, she sold 38,716 shares of common stock at a price of $1.2632 per share.
• On January 14, 2025, she sold 5,088 shares of common stock at a price of $1.2632 per share.
• These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• The sales were executed under a pre-existing 10b5-1 plan, indicating that the CFO had irrevocably elected to satisfy tax obligations through these sales.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The sales are part of a pre-planned arrangement to cover tax obligations, so they don't necessarily reflect a negative view of the company's prospects, but insider selling can sometimes create uncertainty.

Positives

• The sales were pre-planned under a 10b5-1 plan, suggesting they were not based on current market sentiment or inside information.

Risks

• While the sales are for tax obligations, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

Insider sales are a common occurrence, especially when related to tax obligations on vested equity. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on inside information.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the pre-planned nature of the sales should mitigate concerns.

Key Dates